Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
itching
Biotech
GSK’s itch prospect hits mark in phase 3 liver disease trial
The win keeps the drugmaker on track to launch the first treatment for the relentless itching experienced by some liver disease patients.
Nick Paul Taylor
Nov 19, 2024 8:24am
Connect uncouples from Pfizer by scrapping eczema pact
Apr 17, 2024 6:38am
Itch treater Cara cuts 50% of team to extend runway into 2026
Jan 22, 2024 9:44am
Breaking the vicious itch-scratch cycle via 'miswired' neurons
Jul 14, 2022 5:08am
Evommune snags $83M for "Tylenol for itch," three other programs
Sep 9, 2021 7:30am
Cara's stock tanks as atopic dermatitis phase 2 misses endpoint
Apr 30, 2021 8:25am
